Open AccessImmunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
Author(s) -
Nicola P. Klein,
Remon AbuElyazeed,
Michael Povey,
Mercedes Macías Parra,
Javier DíezDomingo,
Anitta Ahonen,
Tiina Korhonen,
Juan-Carlos Tinoco,
Leonard B. Weiner,
Gary S. Marshall,
Peter Silas,
Kwabena O. Sarpong,
Keith P. Ramsey,
John A. Fling,
David Speicher,
Maribel Campos,
Iona Munjal,
Christopher B. Peltier,
Timo Vesikari,
Carmen Baccarini,
Adrian Caplanusi,
Paul Gillard,
Stéphane Carryn,
Ouzama Henry
Publication year - 2019
Publication title -
journal of the pediatric infectious diseases society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 31
eISSN - 2048-7207
pISSN - 2048-7193
DOI - 10.1093/jpids/piz010
Subject(s) - reactogenicity , medicine , mmr vaccine , measles mumps rubella vaccine , measles , rubella , vaccination , immunogenicity , pediatrics , immunology , antibody
MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this study, we assessed the immunogenicity and safety of another MMR vaccine (MMR-RIT [Priorix, GlaxoSmithKline]) compared with those of the MMR II in 12- to 15-month-old children who received it as a first dose.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom